SEC filings
Incyte (INCY)
Recent filings Incyte made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000879169All filings on SEC.gov
10-QQuarterly report
Quarterly report
Incyte filed its quarterly report for the period ended September 30, 2026, with management discussion covering its commercial drug portfolio and risks affecting future operations. …
8-KCurrent report
Results of Operations and Financial Condition
Incyte reported third-quarter 2026 total revenue of $1.56 billion and total net sales of $1.32 billion, each up 14% from a year earlier, and raised its full-year 2026 total net sales guidance to $5.21–$5.30 billion. …
8-KCurrent report
Other Events
Incyte entered an agreement with the U.S. Centers for Medicare & Medicaid Services under which state Medicaid programs will be able to access Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced…
10-QQuarterly report
Quarterly report
Incyte filed its quarterly report on Form 10-Q for the period ended June 30, 2026. The management discussion and analysis restates forward-looking statements and risk factors, including heavy dependence on JAKAFI/JAKAVI (ruxolitinib)…
8-KCurrent report
Results of Operations and Financial Condition
Incyte reported second-quarter 2026 total revenue of $1.67 billion and total net sales of $1.49 billion, up 38% and 40% respectively from a year earlier, and raised its full-year 2026 total net sales guidance to $5.13–$5.26 billion, citing…
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Incyte in Readster
Add Incyte to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.